New ASH Summit Encourages Practical, Elevated Dialogue on Emerging Immunotherapies
The ASH Summit on Emerging Immunotherapies for Hematologic Diseases program co-chairs Drs. Catherine Bollard, Rodrigo Calado, Sergio Giralt, and Jeffrey Miller share their
Novel Insights From Comprehensive Genomic Profiling of T Cell Acute Lymphoblastic Leukemia
Dr. Teachey reviews a study that helps expand understanding of T-cell acute lymphoblastic leukemia biology.
The Hematologist welcomes letters of up to 200 words. These letters may be in response to editorials or on any subject of interest to our readers. Please include a postal address, e-mail address, and phone number. Publication will be based on editorial decision regarding interest to readers and space availability. We may edit letters for reasons of space or clarity. The Hematologist reserves the right to publish your letter, unless it is labeled "not for publication." Letters should be sent to:
Juana Llorens, Managing EditorThe Hematologist: ASH News and Reports
2021 L Street, NW, Suite 900
Washington, DC 20036
Dr. Robert Peter Gale and Dr. Gerhard Opelz comment on Contributing Editor Dr. Andrew Roberts' article on stopping imatinib therapy in CML.
Dr. Rosenblum responds to The Hematologist Editor-in-Chief's commentary in the Year's Best issue.
Dr. Saultz and Dr. Devine discuss cord blood transplants in patients with MRD as an alternative donor source.
Dr. Akabutu sends Dr. Jason Gotlib a question about the November December 2016 Image Challenge.
Dr. Thomas Bensinger gives his views on why evaluation of the peripheral blood film is often not incorporated into the evaluation of hematology patients and offers solutions to remedy this glaring
Dr. DiMichele outlined the appropriate evaluation that should be performed at presentation. She also gave sound counsel concerning the young woman's request for combined hormonal oral contraceptive pills, an effective treatment for menorrhagia, but complicated in this patient by the family history of thrombophilia. The wise advice here was avoidance of risk factors. The comprehensive nature of Dr. DiMichele's reply is evidenced in her noting the importance of the psychosocial, or quality-of-life, consequences for adolescents who must face these issues.
The National Heart, Lung, and Blood Institute (NHLBI) Transfusion Medicine/Hemostasis Clinical Trials Network has opened a clinical trial to study the role of rituximab in the treatment of thrombotic thrombocytopenic purpura (TTP). The Network was formed in 2002 as a consortium of 18 academic centers to provide opportunities for clinical research on uncommon hematologic disorders.
Earlier this year, the NHLBI convened a working group workshop on the roles of glycans in hemostasis, inflammation, and vascular biology. The Working Group Report has just been published in Glycobiology.
A greater part of the cost of medical care has shifted from insurance companies to the individual patient because of increases in co-pays and deductibles. A consequence of these increases is a change in patient behavior, which is rarely to his or her medical advantage.
I have a few reservations with regard to Dr. Jerald Radich's article "The Wasteland of Relapsed Adult ALL" (March/April 2008 issue).
January-February 2018Volume 15, Issue 1
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology